Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2014

01-05-2014 | Research Article

Transforming growth factor beta1 (TGFβ1) polymorphisms and breast cancer risk

Authors: Davar Amani, Ahad Khalilnezhad, Abbas Ghaderi, Norrio Niikawa, Ko-ichiro Yoshiura

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

Transforming growth factor β1 (TGFβ1) is suggested to be involved in the pathogenesis of and in complications with breast cancer (BC). Polymorphisms in TGFβ1 gene (TGFβ1) have been suggested by many investigators to have a role in susceptibility to BC; however, many discordant data have been reported. Considering the role of ethnic variations, we performed an association study between TGFβ1 polymorphisms and BC among Iranian women. We sequenced DNA samples of 110 BC and 110 normal control women for the exons and their adjacent intronic regions of TGFβ1 using PCR. The allele, genotype, and haplotype frequencies were calculated using PowerMarker V3.25 and R 3.0.2 softwares. Ten single nucleotide polymorphisms (SNPs) were detected. Statistical analysis on the frequency of seven most frequent SNPs, including the three coding SNPs (cSNPs) revealed no significant difference between BC and control women. Moreover, among 11 constructed haplotypes, “GTGCCGC” was significantly different between two study groups. In conclusion, we found no association between the studied SNPs of TGFβ1 and BC among Iranian women, but a possible association between “GTGCCGC” haplotype and BC was seen. However, further studies are suggested to clarify this association.
Literature
1.
Porter PL. Global trends in breast cancer incidence and mortality. Salud Publica Mex. 2009;51:s141–6.CrossRefPubMed
2.
Ikushima H, Miyazono K. TGFbeta signaling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.CrossRefPubMed
3.
Marcoe JP, Lim JR, Schaubert KL, Fodil-Cornu N, Matka M, McCubbrey AL, et al. TGF-beta is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat Immunol. 2012
4.
Ling E, Robinson DS. Transforming growth factor-beta1: its anti-inflammatory and pro-fibrotic effects. Clin Exp Allergy. 2002;32:175–8.CrossRefPubMed
5.
van Meeteren LA, ten Dijke P. Regulation of endothelial cell plasticity by TGF-beta. Cell Tissue Res. 2012;347:177–86.CrossRefPubMed
6.
Ikushima H, Miyazono K. Biology of transforming growth factor-beta signaling. Curr Pharm Biotechnol. 2011;12:2099–107.CrossRefPubMed
7.
Fujii D, Brissenden JE, Derynck R, Francke U. Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet. 1986;12:281–8.CrossRefPubMed
8.
Wakefield LM, Piek E, Bottinger EP. TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2001;6:67–82.CrossRefPubMed
9.
Babyshkina N, Malinovskaya E, Stakheyeva M, Volkomorov V, Slonimskaya E, Maximov V, et al. Association of functional −509C>T polymorphism in the TGF-beta1 gene with infiltrating ductal breast carcinoma risk in a Russian Western Siberian population. Cancer Epidemiol. 2011;35:560–3.CrossRefPubMed
10.
Woo SU, Park KH, Woo OH, Yang DS, Kim AR, Lee ES, et al. Association of a TGF-beta1 gene −509 C/T polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;124:481–5.CrossRefPubMed
11.
Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, et al. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 2003;63:2610–5.PubMed
12.
Shin A, Shu XO, Cai Q, Gao YT, Zheng W. Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev. 2005;14:1567–70.CrossRefPubMed
13.
Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998;66:1014–20.CrossRefPubMed
14.
Berndt SI, Huang WY, Chatterjee N, Yeager M, Welch R, Chanock SJ, et al. Transforming growth factor beta 1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma. Carcinogenesis. 2007;28:1965–70.CrossRefPubMed
15.
Stoll C, Mengsteab S, Stoll D, Riediger D, Gressner AM, Weiskirchen R. Analysis of polymorphic TGFB1 codons 10, 25, and 263 in a German patient group with non-syndromic cleft lip, alveolus, and palate compared with healthy adults. BMC Med Genet. 2004;5:15.CrossRefPubMedPubMedCentral
16.
Wei YS, Xu QQ, Wang CF, Pan Y, Liang F, Long XK. Genetic variation in transforming growth factor-beta1 gene associated with increased risk of esophageal squamous cell carcinoma. Tissue Antigens. 2007;70:464–9.CrossRefPubMed
17.
Zhang P, Di JZ, Zhu ZZ, Wu HM, Wang Y, Zhu G, et al. Association of transforming growth factor-beta 1 polymorphisms with genetic susceptibility to TNM stage I or II gastric cancer. Jpn J Clin Oncol. 2008;38:861–6.CrossRefPubMed
18.
Amani D, Dehaghani AS, Zolghadri J, Ravangard F, Niikawa N, Yoshiura K, et al. Lack of association between the TGF-beta1 gene polymorphisms and recurrent spontaneous abortion. J Reprod Immunol. 2005;68:91–103.CrossRefPubMed
19.
Amani D, Zolghadri J, Dehaghani AS, Pezeshki AM, Ghaderi A. The promoter region (−800, −509) polymorphisms of transforming growth factor-beta1 (TGF-beta1) gene and recurrent spontaneous abortion. J Reprod Immunol. 2004;62:159–66.CrossRefPubMed
20.
Derynck R, Rhee L, Chen EY, Van Tilburg A. Intron-exon structure of the human transforming growth factor-beta precursor gene. Nucleic Acids Res. 1987;15:3188–9.CrossRefPubMedPubMedCentral
21.
Feizollahzadeh S, Taheripanah R, Khani M, Farokhi B, Amani D. Promoter region polymorphisms in the transforming growth factor beta-1 (TGFbeta1) gene and serum TGFbeta1 concentration in preeclamptic and control Iranian women. J Reprod Immunol. 2012;94:216–21.CrossRefPubMed
22.
Skerrett DL, Moore EM, Bernstein DS, Vahdat L. Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Investig. 2005;23:208–14.CrossRef
23.
Ziv E, Cauley J, Morin PA, Saiz R, Browner WS. Association between the T29→C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. JAMA. 2001;285:2859–63.CrossRefPubMed
24.
Jin Q, Hemminki K, Grzybowska E, Klaes R, Soderberg M, Zientek H, et al. Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer. 2004;112:94–9.CrossRefPubMed
25.
Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE. T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev. 2004;13:412–5.PubMed
26.
Lee KM, Park SK, Hamajima N, Tajima K, Yoo KY, Shin A, et al. Genetic polymorphisms of TGF-beta1 & TNF-beta and breast cancer risk. Breast Cancer Res Treat. 2005;90:149–55.CrossRefPubMed
27.
Shu XO, Gao YT, Cai Q, Pierce L, Cai H, Ruan ZX, et al. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res. 2004;64:836–9.CrossRefPubMed
28.
Cox DG, Penney K, Guo Q, Hankinson SE, Hunter DJ. TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses’ Health Study. BMC Cancer. 2007;7:175.CrossRefPubMedPubMedCentral
29.
Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, et al. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res. 2005;65:3454–61.PubMed
30.
Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett. 2003;201:181–4.CrossRefPubMed
31.
Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007;39:352–8.CrossRefPubMed
32.
Hishida A, Iwata H, Hamajima N, Matsuo K, Mizutani M, Iwase T, et al. Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer. 2003;10:63–9.CrossRefPubMed
33.
Ma X, Chen C, Xiong H, Li Y. Transforming growth factorbeta1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls. Breast Cancer Res Treat. 2010;124:453–7.CrossRefPubMed
34.
Scollen S, Luccarini C, Baynes C, Driver K, Humphreys MK, Garcia-Closas M, et al. TGF-beta signaling pathway and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2011;20:1112–9.CrossRefPubMedPubMedCentral
35.
Mu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, et al. TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. Br J Cancer. 2008;99:1357–63.CrossRefPubMedPubMedCentral
36.
Breast Cancer Association C. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst. 2006;98:1382–96.CrossRef
37.
Amani D, Farjadian S, Ghaderi A. The frequency of transforming growth factor-beta1 gene polymorphisms in a normal southern Iranian population. Int J Immunogenet. 2008;35:145–51.CrossRefPubMed
38.
39.
Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics. 2005;21:2128–9.CrossRefPubMed
40.
Vuong MT, Lundberg S, Gunnarsson I, Wramner L, Seddighzadeh M, Hahn-Zoric M, et al. Genetic variation in the transforming growth factor-beta1 gene is associated with susceptibility to IgA nephropathy. Nephrol Dial Transplant. 2009;24:3061–7.CrossRefPubMedPubMedCentral
41.
Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29→C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation. 2000;101:2783–7.CrossRefPubMed
42.
Beisner J, Buck MB, Fritz P, Dippon J, Schwab M, Brauch H, et al. A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer. Cancer Res. 2006;66:7554–61.CrossRefPubMed
43.
Ma X, Beeghly-Fadiel A, Lu W, Shi J, Xiang YB, Cai Q, et al. Pathway analyses identify TGFBR2 as potential breast cancer susceptibility gene: results from a consortium study among Asians. Cancer Epidemiol Biomarkers Prev. 2012;21:1176–84.CrossRefPubMed
44.
Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, et al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res. 1998;13:1569–76.CrossRefPubMed
45.
Pelletier R, Pravica V, Perrey C, Xia D, Ferguson RM, Hutchinson I, et al. Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation. 2000;70:674–80.CrossRefPubMed
46.
Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta. 2002;316:83–94.CrossRefPubMed
47.
Feigelson HS, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE. Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1236–7.CrossRefPubMed
48.
Barnett GC, Coles CE, Burnet NG, Pharoah PD, Wilkinson J, West CM, et al. No association between SNPs regulating TGF-beta1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother Oncol. 2010;97:9–14.CrossRefPubMedPubMedCentral
49.
Band AM, Laiho M. Crosstalk of TGF-beta and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2011;16:109–15.CrossRefPubMed
50.
Joshi NN, Kale MD, Hake SS, Kannan S. Transforming growth factor beta signaling pathway associated gene polymorphisms may explain lower breast cancer risk in western Indian women. PLoS One. 2011;6:e21866.CrossRefPubMedPubMedCentral
51.
Langdahl BL, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S, Brandi ML, et al. Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone. 2008;42:969–81.CrossRefPubMed
52.
Keen RW, Snieder H, Molloy H, Daniels J, Chiano M, Gibson F, et al. Evidence of association and linkage disequilibrium between a novel polymorphism in the transforming growth factor beta 1 gene and hip bone mineral density: a study of female twins. Rheumatology (Oxford). 2001;40:48–54.CrossRef
53.
Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone. 2003;32:297–310.CrossRefPubMed
54.
Bertoldo F, D’Agruma L, Furlan F, Colapietro F, Lorenzi MT, Maiorano N, et al. Transforming growth factor-beta1 gene polymorphism, bone turnover, and bone mass in Italian postmenopausal women. J Bone Miner Res. 2000;15:634–9.CrossRefPubMed
55.
Weinshenker BG, Hebrink D, Kantarci OH, Schaefer-Klein J, Atkinson E, Schaid D, et al. Genetic variation in the transforming growth factor beta1 gene in multiple sclerosis. J Neuroimmunol. 2001;120:138–45.CrossRefPubMed
Metadata
Title
Transforming growth factor beta1 (TGFβ1) polymorphisms and breast cancer risk
Authors
Davar Amani
Ahad Khalilnezhad
Abbas Ghaderi
Norrio Niikawa
Ko-ichiro Yoshiura
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1621-x

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue

Research Article

An analysis of the most-cited research papers on oncology: which journals have they been published in?

Research Article

Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma

Research Article

Association between p53 codon 72 polymorphism and sarcoma risk among Caucasians

Research Article

Expression and clinical significance of BIRC6 in human epithelial ovarian cancer

Research Article

Microsatellite instability and promoter hypermethylation in colorectal cancer in India

Research Article

Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits